“…In particular, a significant correlation between NOTCH1 M and higher CD49d or CD38 expressions was observed, as well a trend towards an association between NOTCH1 M and IGHV UM status, in keeping with previous observations by us and others. 27 , 21 , 4 , 28 Further, co-occurrence of NOTCH1 M and TP53 M characterized 13% of our patients (23 of 178), a rather high percentage if compared to previous reports where concomitant NOTCH1 M and TP53 M, preferentially affecting the same leukemic cells, 29 accounted for 1.2-2.6% of CLL patients. 20 , 23 This may be due to the high number of pre-treated patients and to the low cut-off chosen by us for NOTCH1 M detection.…”